Candel Therapeutics (CADL) Asset Writedowns and Impairment (2023 - 2025)

Candel Therapeutics has disclosed Asset Writedowns and Impairment across 3 years of filings, most recently posting $7000.0 for Q4 2025.

• Asset Writedowns and Impairment for Q4 2025 came in at $7000.0, down 82.93% year-over-year; the trailing twelve-month figure through Dec 2025 was $277000.0 (changed N/A YoY), and the FY2025 annual result was $90000.0, up 119.51% from the prior year.
• Asset Writedowns and Impairment came in at $7000.0 for Q4 2025 at Candel Therapeutics, up from $1000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $228000.0 in Q4 2023 to a low of $1000.0 in Q3 2025.
• The 3-year median for Asset Writedowns and Impairment is $24000.0 (2024), against an average of $69250.0.
• Across the five-year window, Asset Writedowns and Impairment plunged 82.02% in 2024 and slumped 82.93% in 2025, its largest moves.
• Candel Therapeutics' Asset Writedowns and Impairment stood at $228000.0 in 2023, then slumped by 82.02% to $41000.0 in 2024, then plunged by 82.93% to $7000.0 in 2025.
• The last three Asset Writedowns and Impairment figures came in at $7000.0 (Q4 2025), $1000.0 (Q3 2025), and $41000.0 (Q4 2024), per Business Quant data.